Bikash Chatterjee and Stephanie Gaulding, CEO and MD at drug development consultancy firm Pharmatech Associates, talk about the different partnering and outsourcing strategies innovators can take, with a specific focus on smaller and mid-sized biotechs, which often don’t have the same level of in-built CMC expertise as Big Pharma. Whether you go with a single end-to-end CDMO or a multi-model approach, one thing is clear: know your product, know your needs and plan early.

This conversation originally took place as a Linkedin Live event ahead of the CPhI Worldwide conference happening in Frankfurt in November.